TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have had a diagnosis of plaque-type psoriasis at least 6 months prior to the study~* Have plaque-type psoriasis covering at least 10 percentage of total body surface area~* Have a Psoriasis Area and Severity Index (PASI) score of 12 or greater and a Physician's Global Assessment (PGA) score of 3 or greater at the time of the first administration of study drug~* Must be suitable for phototherapy or systemic treatment for psoriasis~* Have failed to respond to or have condition which prevents use of cyclosporine, methotrexate (MTX) or psoralen plus ultraviolet light A (PUVA)~Exclusion Criteria:~* Currently have nonplaque forms of psoriasis~* Have current drug-induced psoriasis~* Have used any therapeutic agent targeted at reducing interleukin-12 (IL-12) or IL-23 (Interleukins are the substance produced by body in immunological disease like psoriasis)~* Have received phototherapy or any systemic medications/treatments that could affect psoriasis or PASI evaluation (including, but not limited to, oral or injectable corticosteroids, retinoids, 1,25 dihydroxy vitamin D3 and analogues, psoralens, sulfasalazine, hydroxyurea, or fumaric acid derivatives) within 4 weeks of the first administration of study agent~* Have used a biologic within the previous 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CNTO 1275 45 mg (Type: EXPERIMENTAL): Patients will receive CNTO 1275 45 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on Physician's Global Assessment (PGA) response at Week 12 and initial treatment assignment.
- CNTO 1275 90 mg (Type: EXPERIMENTAL): Patients will receive CNTO 1275 90 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.
- Etanercept 50 mg (Type: ACTIVE_COMPARATOR): Patients will receive Etanercept 50 mg twice weekly through Week 12. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older patients suffering from OAB symptoms (urinary frequency of at least 8 micturitions per 24h, urinary urgency and at least 3 urge urinary incontinence episodes within 3 days), confirmed by a micturition bladder diary.~Exclusion Criteria:~* Other than urge incontinence~* History of prostate/uterine or other female organ cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Patient-Centered Strategy for Improving Diabetes Prevention in Urban American Indians

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Urban of Indigenous Ancestry from the Americas (North, Central and South America)~* Men and women~* BMI Between 30-55~* Not diagnosed with Type II Diabetes~* At least one of the following criterion~  1. Triglycerides: 150mg/dL or higher~ 2. Reduced HDL: \<40mg/dL (men); \<50mg/dL (women)~ 3. Blood pressure: \>130/80 or current treatment with antihypertensives~ 4. Fasting glucose: \>100mg/dL~Exclusion Criteria:~* Significant medical comorbidities, including uncontrolled metabolic disorders (e.g., thyroid, diabetes, renal, liver), unstable heart disease, heart failure, and ongoing substance abuse;~* On greater than 10 prescription medications.~* Psychiatric disorders requiring atypical antipsychotics or multiple medications;~* Inappropriate for moderate exercise according to the Revised Physical Activity Readiness Questionnaire;~* Pregnant, planning to become pregnant, or lactating;~* Family household member already enrolled in the study;~* Already enrolled or planning to enroll in a clinical trial that would limit full participation in the study;~* Resident of a long term care facility;~* Lack of spoken English by patient or a household member \> 18 y who can serve as interpreter;~* Plans to move during the study period (9 months post-randomization);~* Investigator discretion for clinical safety or adherence reasons (e.g., unstable housing, chronic pain).

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Standard Diabetes Prevention Program (DPP) (Type: ACTIVE_COMPARATOR): Participants receive Standard DPP over the course of 20 weeks.
- Enhanced DPP (Type: EXPERIMENTAL): Participants receive Standard DPP plus Enhanced DPP over the course of 20 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Capable and willing to provide written informed consent or assent~* Documented diagnosis of PH1 or PH2, confirmed by genotyping~* Must meet the 24 hour urine oxalate excretion requirements~* Less than 20% variation between the two 24-hour urinary creatinine excretion values derived from the two 24-hour urine collections in the screening period~* Estimated GFR at screening ≥ 30 mL/min normalized to 1.73 m2 BSA~Key Exclusion Criteria:~* Renal or hepatic transplantation (prior or planned within the study period)~* Currently on dialysis or anticipated requirement for dialysis during the study period~* Plasma oxalate \>30 µmol/L~* Documented evidence of clinical manifestations of systemic oxalosis (including pre-existing retinal, heart, or skin calcifications, or history of severe bone pain, pathological fractures, or bone deformations)~* Use of an RNA interference (RNAi) drug within the last 6 months~* Participation in any clinical study in which you received an investigational medicinal product (IMP) within 4 months before Screening~* Liver function test (LFT) abnormalities: Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>1.5 times upper limit of normal (ULN) for age and gender~* Inability or unwillingness to comply with study procedures

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DCR-PHXC (Type: EXPERIMENTAL): Intervention, drug, DCR-PHXC
- Placebo - Sterile Normal Saline (0.9% NaCl) (Type: PLACEBO_COMPARATOR): Placebo, sterile normal saline (0.9% NaCl) for subcutaneous (SC) injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Learning Impairments Among Survivors of Childhood Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 6 to 18 years old.~* Active subject at St. Jude Children's Research Hospital, or is an age-matched sibling control subject.~* If a subject, received treatment for brain tumor or ALL with either radiation therapy and/or chemotherapy directed at the brain.~* If a subject, at least 12 months post-completion of antineoplastic therapies~* If a subject, no evidence of malignancy, or continuously stable disease since completion of therapy~* English as a primary language~* Informed consent~Exclusion Criteria:~* Glaucoma~* Patient or immediate family member with a history of Tourette's syndrome~* Current antidepressant, anxiolytic, antipsychotic or stimulant therapy~* History of substance abuse~* Recent history of uncontrolled seizures~* Uncorrected hypothyroidism~* Previously or currently randomized on COGRM1 intervention arm~* Previously diagnosed with ADHD, or, if a patient, diagnosed with ADHD prior to diagnosis of malignancy

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with confirmed HIV infection~* Age ≥ 18 years~* Written informed consent~* Male patient or non-pregnant, non-lactating female~* No previous treatment with any antiretroviral drugs~* HIV-1 RNA \> 1000 copies/ml~* Indication to start an antiretroviral treatment as long as subject has also a CD4 cell count ≤ 500/mm3 either at screening or on a sample taken within 3 months before screening~* No major IAS-USA mutations on genotypic testing at the screening visit or on any historical genotype, if available~Non-inclusion Criteria:~* Woman without effective contraception method (recommended contraception during the trial is mechanical + a second method other than an oral contraceptive)~* Pregnant or breastfeeding woman~* Woman expecting to conceive during the study~* HIV-2 co-infection~* Creatinine clearance \< 60 ml/mn (Cockcroft \& Gault equation), alkaline phosphatase, ASAT, or ALAT ≥ 5 ULN~* Patient with significant impairment of hepatic function, defined as serum albumin \< 2.8 g/dl or INR \> 1.7 or presence of ascites, in the absence of another explanation for the abnormal finding~* CD4 \> 500/mm3 at screening, except in case of symptomatic HIV disease (defined by conditions qualifying for CDC category B or C) or CD4 ≤ 500/mm3 on a sample taken within 3 months before screening.~* Any major IAS-USA mutation conferring resistance to one or more of reverse transcriptase or protease inhibitors on genotypic testing at screening~* Mycobacteriosis under treatment~* Malignancy requiring chemotherapy or radiotherapy~* Positive HBs Ag~* HCV infection for which specific treatment is ongoing or planned during the first year on trial treatment~* Known hypersensitivity to one of the trial drugs or its excipients~* Contraindicated concomitant treatment~* Anticipated non-compliance with the protocol~* Participation in another clinical trial with an on-going exclusion period at screening~* Subject under legal guardianship or incapacitation~* Subject, who in the opinion of the investigator, is unable to complete the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- darunavir/r + tenofovir/emtricitabine (Type: ACTIVE_COMPARATOR): None
- darunavir/r + raltegravir (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cobalamin Supplementation During Infancy; Effect on B-vitamin Status, Growth and Psychomotor Development

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 6 weeks old infants~* The infant should be healthy and not have any serious malformations~* The mother should be healthy and not have any serious disorders or use any daily medications~* The mother should have an ordinary omnivorous diet~Exclusion Criteria:~* If there are evidence of serious infant disease during the study period, the infant should be excluded from the study

- Gender: ALL
- Minimum Age: 4 Weeks
- Maximum Age: 4 Months
- Healthy Volunteers: t

Study Arms:
- Cobalamin (Type: EXPERIMENTAL): An intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
- No intervention (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted patients who meets the clinical definition for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)~* Known or suspected gram-positive infection.~Exclusion Criteria:~* Known or suspected gram-negative infections, anaerobic infections, or fungemia~* Known or suspected infections that are severe, life threatening or are not included in the ABSSSI Food and Drug Administration (FDA) guidance~* Injection drug users with a fever~* Severe neurological disorder leading to immobility or confined to a wheelchair~* Bilateral Lower extremity involvement of the suspected infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- New Critical Pathway (Type: ACTIVE_COMPARATOR): The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
- Usual Care (Type: ACTIVE_COMPARATOR): Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers with a body mass index (BMI, a measure of a person's weight in relation to height) between 18 and 30 kg/m2, inclusive, and a body weight of not less than 50 kg~Exclusion Criteria:~* History of or current clinically significant medical illness as determined by the Investigator~* History of clinically significant allergies, especially known hypersensitivity or intolerance to lactose~* Known allergy to canagliflozin or any of the excipients of the formulation of canagliflozin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 001 (Type: EXPERIMENTAL): Canagliflozin 300 mg once daily and 150 mg twice daily Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
- 002 (Type: EXPERIMENTAL): Canagliflozin 100 mg once daily and 50 mg twice daily Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed Hodgkin's lymphoma of the classical type (nodular lymphocyte predominance excluded).~* Stage IIB-IV.~* Age 18-70.~* No prior therapy for Hodgkin's lymphoma~* Written informed consent.~* ECOG performance status grades 0-3 (see Appendix E).~* FDG-PET scan before the initiation of treatment.~Exclusion Criteria:~* Prior therapy for Hodgkin's lymphoma.~* Age less than 18 or more than 70.~* Other concomitant or prior malignancies, except basal cell skin carcinoma, or adequately treated carcinoma in situ of the cervix, or any cancer in complete remission for more than 5 years.~* HIV infection.~* Pregnancy or breast-feeding.~* Renal failure (creatinine ≥2 times the normal value), liver failure (AST/ALT or bilirubine ≥ 2.5 times the normal value) or heart failure (NYHA class ≥ 2 or FEV \< 45%).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: OTHER): Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)~The subsequent treatment will be as it follows:~* PET-2 positive patients will be high-dose salvage treatment;~* PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).~The following restaging procedures are planned as it follows:~* Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.~* Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).~PET-6 negative patients will be randomized to first arm:~No radiotherapy.
- Arm B (Type: OTHER): Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)~The subsequent treatment will be as it follows:~* PET-2 positive patients will be high-dose salvage treatment;~* PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).~The following restaging procedures are planned as it follows:~* Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.~* Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).~PET-6 negative patients will be randomized to second arm:~Adjuvant radiotherapy (30 Gy) on sites of initial bulky disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Chronic HCV genotype 1-infection prior to study enrollment. Chronic HCV-infection is defined as the following:~   * Positive for anti-HCV antibody (Ab) or HCV RNA \> 1,000 IU/mL at least 6 months before Screening, and positive for HCV RNA and anti-HCV Ab at the time of Screening; or~  * HCV RNA \> 1,000 IU/mL at the time of Screening with a liver biopsy consistent with chronic HCV-infection (or a liver biopsy performed prior to enrollment with evidence of chronic hepatitis C disease).~2. Screening laboratory result indicating HCV genotype 1b-infection.~3. Compensated cirrhosis defined as a Child-Pugh Score of 5 or 6 at Screening.~Exclusion Criteria:~1. Women who are pregnant or breastfeeding.~2. Positive test result for Hepatitis B surface antigen (HBsAg) or positive human immunodeficiency virus (HIV) antibody (confirmed by Western Blot).~3. Any current or past clinical evidence of Child-Pugh B or C classification or clinical history of liver decompensation such as ascites (noted on physical exam), variceal bleeding, or hepatic encephalopathy.~4. Confirmed presence of hepatocellular carcinoma indicated on imaging techniques such as computed tomography (CT) scan or magnetic resonance imaging (MRI) within 3 months prior to Screening or on an ultrasound performed at Screening (a positive ultrasound result will be confirmed with CT scan or MRI.)~5. Use of contraindicated medications within 2 weeks of dosing~6. Screening laboratory analyses showing any of the following abnormal laboratory results:~   * Calculated creatinine clearance (using Cockcroft-Gault method) \< 30 mL/min~  * Albumin \< 2.8 g/dL~  * International normalized ratio (INR) \> 1.8. Participants with a known inherited blood disorder and INR \> 1.8 may be enrolled with permission of the AbbVie Study Designated Physician.~  * Hemoglobin \< 10 g/dL~  * Platelets \< 25,000 cells per mm3~  * Total bilirubin \> 3.0 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir (Type: EXPERIMENTAL): Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete